Description
PROLASTIN FOR THE SYRACUSE VAMC
First action · last action
2014-10-07 · 2015-09-24
Transactions
2
First transaction's obligation
$221,760
Base + all options value (sum of deltas)
$143,750
Extent competed
FULL AND OPEN COMPETITION
Other than full & open authority
—
Set-aside
NO SET ASIDE USED.
Offers received
—
SDVOSB flag on record
No
Parent IDV
VA797P13A0002
NAICS
325412 · PHARMACEUTICAL PREPARATION MANUFACTURING
Modification chain · 2 transactions
Each row is one published transaction. This action is the obligation recorded on that transaction — a change amount, as USAspending publishes it. Running total is computed by Glassbox VA as the cumulative sum of those amounts up to and including the row, so the last running total equals the award's net obligations shown above. The cumulative-total columns in the source files are not used: they are not frozen per modification.
- Base2014-10-07+$221,760= $221,760
- Mod P000012015-09-24-$78,010= $143,750
| Transaction | Action date | This action (delta) | Running total | Description on this transaction |
|---|---|---|---|---|
| Base | 2014-10-07 | +$221,760 | $221,760 | PROLASTIN FOR THE SYRACUSE VAMC |
| Mod P00001· CHANGE ORDER | 2015-09-24 | −$78,010 | $143,750 | PROLASTIN FOR THE SYRACUSE VAMC |
Related awards · 11
Awards are related by an explicit link in the data, stated for each group below — never by text similarity. Values are net obligations.
Other VA awards to the same recipient (UEI UFQ3A7GKJ5C7)
| Award | Office · PSC / listing | Net obligations | FY |
|---|---|---|---|
| 36C26022F0140 | 260-NETWORK CONTRACT OFFICE 20 (36C260) · 6505 · DRUGS AND BIOLOGICALS | $100,282 | FY2022 |
| 36C26022F0004 | 260-NETWORK CONTRACT OFFICE 20 (36C260) · 6505 · DRUGS AND BIOLOGICALS | $454,461 | FY2022 |
| 36C26021F0264 | 260-NETWORK CONTRACT OFFICE 20 (36C260) · 6505 · DRUGS AND BIOLOGICALS | $130,406 | FY2021 |
| 36C26021F0117 | 260-NETWORK CONTRACT OFFICE 20 (36C260) · 6505 · DRUGS AND BIOLOGICALS | $75,000 | FY2021 |
| 36C26021F0014 | 260-NETWORK CONTRACT OFFICE 20 (36C260) · 6505 · DRUGS AND BIOLOGICALS | $220,000 | FY2021 |
| 36C26021F0021 | 260-NETWORK CONTRACT OFFICE 20 (36C260) · 6505 · DRUGS AND BIOLOGICALS | $355,273 | FY2021 |
Other recipients under 6505 from 242-NETWORK CONTRACT OFFICE 02 (most recent first)
| Award | Recipient | Office | Net obligations | FY |
|---|---|---|---|---|
| VA52816F0890 | PFIZER INC | 242-NETWORK CONTRACT OFFICE 02 | $10,346 | FY2016 |
| VA52816F0808 | BAYER HEALTHCARE PHARMACEUTICALS INC | 242-NETWORK CONTRACT OFFICE 02 | $16,180 | FY2016 |
| VA52816F0388 | CSL BEHRING L.L.C. | 242-NETWORK CONTRACT OFFICE 02 | $1,097 | FY2016 |
| VA24016E0142 | MCKESSON CORPORATION | 242-NETWORK CONTRACT OFFICE 02 | $5,517,543 | FY2016 |
| VA52816J0701 | CEPHEID | 242-NETWORK CONTRACT OFFICE 02 | $234,636 | FY2016 |
Cite as: Glassbox VA record view · VA contract (USAspending / FPDS) · CONT_AWD_VA52815F0014_3600_VA797P13A0002_3600 · retrieved 2026-09-26.